UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 147

Sortiert nach

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)

Lung cancer (Amsterdam, Netherlands), 2014-08, Vol.85 (2), p.306-313

2014

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study

British journal of cancer, 2006-04, Vol.94 (8), p.1099-1106

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

Annals of oncology, 2002-10, Vol.13 (10), p.1539-1549

2002

Link zum Volltext

Verfügbarkeit prüfen

The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression

British journal of cancer, 2001-05, Vol.84 (10), p.1372-1376

2001

Link zum Volltext

Verfügbarkeit prüfen

Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability

British journal of cancer, 2005-09, Vol.93 (6), p.719-729

2005

Link zum Volltext

Verfügbarkeit prüfen

Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway

Cell death and differentiation, 2002-09, Vol.9 (9), p.905-914

2002

Link zum Volltext

Verfügbarkeit prüfen

Origin and prognostic value of circulating KRAS mutations in lung cancer patients

Cancer letters, 2007-09, Vol.254 (2), p.265-273

2007

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

Annals of oncology, 2015-04, Vol.26 (4), p.709-714

2015

Link zum Volltext

Verfügbarkeit prüfen

Resilience and unmet supportive care needs in patients with cancer during early treatment: A descriptive study

European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2015-10, Vol.19 (5), p.582-588

2015

Link zum Volltext

Verfügbarkeit prüfen

Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03

Annals of oncology, 2008-04, Vol.19 (4), p.739-745

2008

Link zum Volltext

Verfügbarkeit prüfen

Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study

Annals of oncology, 2004-03, Vol.15 (3), p.511-516

2004

Link zum Volltext

Verfügbarkeit prüfen

Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)

Annals of oncology, 2006-10, Vol.17 (10), p.1546-1552

2006

Link zum Volltext

Verfügbarkeit prüfen

Cyclin D1 Overexpression in Bronchial Epithelia of Patients With Lung Cancer Is Associated With Smoking and Predicts Survival

Journal of clinical oncology, 2003-06, Vol.21 (11), p.2085-2093

2003

Link zum Volltext

Verfügbarkeit prüfen

Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer

British journal of cancer, 1996-02, Vol.73 (3), p.294-300

1996

Link zum Volltext

Verfügbarkeit prüfen

S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas

British journal of cancer, 2004-10, Vol.91 (8), p.1515-1524

2004

Link zum Volltext

Verfügbarkeit prüfen

Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer

British journal of cancer, 1999-02, Vol.79 (5-6), p.952-958

1999

Link zum Volltext

Verfügbarkeit prüfen

Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small cell lung cancer: A multicenter phase II trial (SAKK 15/12)

Annals of oncology, 2018-10, Vol.29, p.viii597-viii597

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

ESMO open, 2022-04, Vol.7 (2), p.100455-100455, Article 100455

2022

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14

ESMO open, 2023-08, Vol.8 (4), p.101595-101595, Article 101595

2023

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]

ESMO open, 2022-06, Vol.7 (3), p.100494-100494, Article 100494

2022

Link zum Volltext

Verfügbarkeit prüfen

Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours

Lung cancer (Amsterdam, Netherlands), 2001-08, Vol.33 (2), p.229-239

2001

Link zum Volltext

Verfügbarkeit prüfen

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies

British journal of cancer, 1999-03, Vol.79 (7-8), p.1215-1219

1999

Link zum Volltext

Verfügbarkeit prüfen

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study

British journal of cancer, 1995-12, Vol.72 (6), p.1551-1555

1995

Link zum Volltext

Verfügbarkeit prüfen

Expression profiling of primary non-small cell lung cancer for target identification

Oncogene, 2002-10, Vol.21 (50), p.7749-7763

2002

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab and breast cancer

The New England journal of medicine, 2001-09, Vol.345 (13), p.996

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 147

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(117)

Publikationsform

Artikel
(145)
Berichte
(1)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(93)
Life Sciences & Biomedicine
(74)
Science & Technology
(74)
Female
(61)
Aged
(58)
Biological And Medical Sciences
(56)
Male
(56)
Middle Aged
(55)
Oncology
(53)
Medical Sciences
(46)
Adult
(43)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(22)
Chemotherapy
(22)
Lung Neoplasms - Drug Therapy
(22)
Lung Neoplasms - Pathology
(22)
Aged, 80 And Over
(21)
Carcinoma, Non-Small-Cell Lung - Pathology
(21)
Neoplasm Staging
(20)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(18)
Pharmacology. Drug Treatments
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(27)
Journal Of Clinical Oncology
(14)
British Journal Of Cancer
(11)
Lung Cancer
(8)
Schweizerische Medizinische Wochenschrift
(8)
British Journal Of Haematology
(6)
Oncogene
(5)
Blood
(4)
Leukemia & Lymphoma
(4)
Therapeutische Umschau
(4)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)

Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression

Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability

Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway

Origin and prognostic value of circulating KRAS mutations in lung cancer patients

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

Resilience and unmet supportive care needs in patients with cancer during early treatment: A descriptive study

Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03

Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study

Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)

Cyclin D1 Overexpression in Bronchial Epithelia of Patients With Lung Cancer Is Associated With Smoking and Predicts Survival

Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer

S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas

Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer

Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small cell lung cancer: A multicenter phase II trial (SAKK 15/12)

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14

Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]

Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study

Expression profiling of primary non-small cell lung cancer for target identification

Trastuzumab and breast cancer

Suchergebnisse filtern